New insider activity at United Therapeutics ( (UTHR) ) has taken place on February 26, 2025.
President & COO Michael Benkowitz recently sold 403 shares of United Therapeutics stock, amounting to a transaction value of $146,204.
Recent Updates on UTHR stock
In the last 24 hours, United Therapeutics experienced a price target adjustment from UBS, which lowered its target from $475 to $460 while maintaining a Buy rating. This change reflects the modest impact of Winrevair on Tyvaso sales. Despite this adjustment, the firm remains optimistic about United Therapeutics due to anticipated developments in idiopathic pulmonary fibrosis (IPF) treatments and advancements in xenotransplantation. Additionally, United Therapeutics announced the full enrollment of the TETON 1 study, which evaluates nebulized Tyvaso for IPF, and received FDA clearance for a clinical study of its investigational UKidney derived from gene-edited pigs. These developments are expected to support future regulatory filings and potential market expansions.
More about United Therapeutics
YTD Price Performance: -0.56%
Average Trading Volume: 334,067
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $15.99B